Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Acute Pancreatitis
The goal of the study is to evaluate the safety and efficacy of multimodal (cytokine and lipopolysaccharide) hemoperfusion using the Efferon® LPS device in combination with hemofiltration (HF) / hemodiafiltration (HDF), with the goal of reducing the severity of organ dysfunction (measured by SOFA score) in patients with acute pancreatitis. Participants will be assigned to two groups for comparison: a control group receiving baseline therapy with HF/HDF, and a treatment group receiving baseline therapy in combination with HF/HDF and Efferon® LPS hemoadsorption.The therapy will be initiated within the first 24 hours after ICU admission and within 8 hours after patient enrollment.
• ≤ 5 days from the onset of acute pancreatitis
• Acute pancreatitis of moderate or severe according to the Atlanta classification (2012)
• Acute pancreatitis confirmed by tomography. Modified CTSI Pancreatitis Severity Index Score ≥ 4 points
• APACHE II \> 8
• ≥ 2 points on the Sequential Organ Failure Assessment (SOFA) scale and/or ≥ 2 criteria of Systemic Inflammatory Response Syndrome (SIRS):
• Body temperature ≥ 38 °C or ≤ 36 °C
• Heart rate ≥ 90/min
• Respiratory rate ≥ 20/min or hyperventilation with PaCO₂ ≤ 32 mmHg
• Leukocytosis (≥ 12,000/μl) or leukopenia (≤ 4,000/μl) or left shift of leukocyte formula